Naturally Occurring and Experimental Diabetes in Cynomolgus Monkeys: A Comparison of Carbohydrate and Lipid Metabolism and Islet Pathology

• Published in: Toxicologic pathology 2001-01, Vol.29 (1), p.142-148
• Main Authors: Wagner, Janice D., Cline, J. Mark, Shadoan, Melanie K., Bullock, Bill C., Rankin, Samuel E., Cefalu, William T.
• Format: Article
• Language: English
• Subjects: Animals; Biological and medical sciences; Carbohydrate Metabolism; Diabetes Mellitus - metabolism; Diabetes Mellitus - pathology; Diabetes Mellitus, Experimental - metabolism; Diabetes Mellitus, Experimental - pathology; Diabetes. Impaired glucose tolerance; Diet, Atherogenic; Disease Progression; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Female; Glucose Tolerance Test; Insulin - blood; Islets of Langerhans - metabolism; Islets of Langerhans - pathology; Lipid Metabolism; Lipids - blood; Lipoproteins - blood; Macaca fascicularis; Male; Medical sciences
• ISSN: 0192-6233; 1533-1601
• DOI: 10.1080/019262301301418955

Diabetes is a major health problem of increasing incidence in the United States. Diabetes research has been limited by lack of availability of good animal models, particularly for the study of comorbidities associated with diabetes. We investigated the use of cynomolgus monkeys as an animal model of both type 1 and type 2 diabetes and compared these naturally occurring diseases with streptozotocin-induced diabetes. Both type 1 diabetics and streptozotocin-induced diabetics present with sudden onset of hyperglycemia and are ketosis prone without exogenous insulin. Type 2 diabetics can have a very long period of moderate hyperglycemia and hypertriglyceridemia and only require exogenous insulin therapy if pancreatic islet reserves are depleted. Type 2 diabetes is preceded by a relatively long period of insulin resistance that is associated with obesity and dyslipidemia. As insulin resistance progresses, islet size and insulin content increases initially. However, with sustained periods of insulin resistance, islet amyloid polypeptide (IAPP) is deposited in islets and can replace normal islet architecture, resulting in an insulin-deficient state. Appearance of IAPP also occurs in human type 2 diabetics but not in conventional rodent models. Unlike type 2 diabetes, neither type 1 nor streptozotocin-induced diabetes is associated with IAPP. Rather, islets can appear normal histologically, but have decreased insulin secretion and immunostaining. Further, the amount of insulin present in the islet is correlated with plasma insulin levels following glucose challenge. Studies are ongoing to determine the pathogenic changes associated with the progression of diabetes and to find novel drug treatments for diabetics.